KNW: AI 评分 47/100 — AI 分析 (4月 2026)

Know Labs, Inc. is a technology company focused on developing and commercializing its Bio-RFID technology, which uses spectroscopy for molecular signature analysis. Their initial application is a non-invasive glucose monitor aimed at providing real-time blood glucose information.

Key Facts: AI Score: 47/100 Sector: Technology

公司概况

概要：

Know Labs, Inc. is a technology company specializing in the development of its proprietary Bio-RFID technology, a spectroscopic approach for identifying molecular signatures. Its primary focus is on creating a non-invasive glucose monitor, positioning it within the competitive medical device hardware market.

KNW是做什么的？

Know Labs, Inc., founded in 1998 and headquartered in Seattle, Washington, is a technology company focused on the development and commercialization of its proprietary Bio-RFID technology. Originally named Visualant, Incorporated, the company rebranded to Know Labs, Inc. in May 2018 to better reflect its evolving focus. The company's core technology, Bio-RFID, utilizes spectroscopy to direct electromagnetic energy through substances, capturing their unique molecular signatures. This technology has potential applications across various industries, but Know Labs is initially targeting the healthcare sector with a non-invasive glucose monitor. The glucose monitor, which integrates Bio-RFID technology, aims to provide users with real-time blood glucose level information without the need for traditional finger pricking. The company envisions its Bio-RFID technology being integrated into wearable, mobile, and bench-top devices, expanding its potential market reach. Know Labs is currently in the development and testing phases for its glucose monitoring product, working towards regulatory approvals and eventual commercialization. The company's success hinges on the accuracy, reliability, and user-friendliness of its Bio-RFID-based glucose monitor, as well as its ability to navigate the complex regulatory landscape of the medical device industry.

KNW的投资论点是什么？

Know Labs, Inc. presents a high-risk, high-reward investment opportunity centered on its Bio-RFID technology and its application in non-invasive glucose monitoring. The company's success depends heavily on the successful development, regulatory approval, and commercialization of its glucose monitor. Key value drivers include the accuracy and reliability of the Bio-RFID technology, the potential market size for non-invasive glucose monitoring, and the company's ability to secure partnerships and distribution channels. Growth catalysts include positive clinical trial results, FDA clearance for its glucose monitor, and strategic collaborations with medical device manufacturers or healthcare providers. However, potential risks include technological hurdles, regulatory delays, competition from established players in the glucose monitoring market, and the company's limited financial resources. With a market capitalization of $0.02 billion and a negative P/E ratio of -0.99, Know Labs is a speculative investment that requires careful consideration of its technological and market risks.

KNW在哪个行业运营？

Know Labs, Inc. operates within the medical device and technology industry, specifically targeting the glucose monitoring market. The global glucose monitoring market is expected to continue growing, driven by the increasing prevalence of diabetes and the demand for more convenient and less invasive monitoring methods. Competition in this market is intense, with established players like Medtronic and Abbott dominating the continuous glucose monitoring (CGM) segment. Know Labs aims to differentiate itself with its non-invasive Bio-RFID technology, but faces challenges in proving its accuracy and reliability compared to existing CGM systems. The company's success will depend on its ability to capture a share of the growing glucose monitoring market by offering a compelling alternative to traditional methods.

Hardware, Equipment & Parts

Technology

KNW有哪些增长机遇？

Expansion into Wearable Devices: Know Labs has the opportunity to integrate its Bio-RFID technology into a variety of wearable devices beyond glucose monitors. This includes potential applications in fitness trackers, smartwatches, and other health-monitoring wearables. The global wearable device market is projected to reach $118.16 billion by 2028, offering a significant growth avenue for Know Labs. Success in this area depends on miniaturizing the Bio-RFID technology and partnering with wearable device manufacturers. Timeline for expansion is estimated at 2-3 years pending technology refinement and partnerships.
Licensing of Bio-RFID Technology: Know Labs can generate revenue by licensing its Bio-RFID technology to other companies in various industries, including healthcare, pharmaceuticals, and environmental monitoring. This would allow the company to leverage its technology without the need for direct product development and manufacturing. The market for spectroscopy-based technologies is substantial, with applications in diverse fields. Licensing agreements could provide a steady stream of revenue and accelerate the adoption of Bio-RFID technology. Timeline for licensing agreements is estimated at 1-2 years.
Development of New Diagnostic Applications: Know Labs can leverage its Bio-RFID technology to develop new diagnostic applications beyond glucose monitoring. This includes potential applications in detecting other biomarkers, such as cholesterol, hormones, and infectious diseases. The market for diagnostic testing is large and growing, driven by the increasing demand for early and accurate disease detection. Successful development of new diagnostic applications would significantly expand Know Labs' market opportunity. Timeline for new diagnostic applications is estimated at 3-5 years, requiring further research and development.
Strategic Partnerships with Healthcare Providers: Know Labs can establish strategic partnerships with healthcare providers, such as hospitals, clinics, and diabetes management centers, to promote and distribute its glucose monitor. These partnerships would provide access to a large patient base and enhance the credibility of the product. The healthcare provider market is increasingly focused on adopting innovative technologies that improve patient outcomes and reduce costs. Successful partnerships would accelerate the adoption of Know Labs' glucose monitor. Timeline for strategic partnerships is estimated at 1-2 years.
International Expansion: Know Labs can expand its operations internationally, targeting markets with a high prevalence of diabetes and a growing demand for advanced medical technologies. This would require adapting its glucose monitor to meet local regulatory requirements and establishing distribution channels in new markets. The global diabetes market is expanding rapidly, particularly in developing countries. Successful international expansion would significantly increase Know Labs' revenue potential. Timeline for international expansion is estimated at 2-3 years, contingent on regulatory approvals and market entry strategies.

Know Labs, Inc. is focused on developing and commercializing its Bio-RFID technology, a spectroscopic method for molecular signature analysis.
The company's initial application of Bio-RFID is a non-invasive glucose monitor aimed at providing real-time blood glucose information.
Know Labs, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
The company's technology can be integrated into wearable, mobile, or bench-top form factors.
Know Labs, Inc. has a market capitalization of $0.02 billion and a beta of 1.76.

KNW提供哪些产品和服务？

Develops Bio-RFID technology using spectroscopy to identify molecular signatures.
Creates non-invasive glucose monitors for real-time blood glucose level information.
Aims to integrate Bio-RFID technology into wearable, mobile, and bench-top devices.
Focuses on commercializing its proprietary technologies in the United States.
Seeks regulatory approvals for its glucose monitoring product.
Conducts research and development to expand the applications of Bio-RFID technology.

KNW如何赚钱？

Develops and patents Bio-RFID technology.
Creates and commercializes medical devices based on Bio-RFID, starting with a glucose monitor.
Potentially licenses Bio-RFID technology to other companies for various applications.
Generates revenue through the sale of glucose monitors and potentially through licensing agreements.

Individuals with diabetes who need to monitor their blood glucose levels.
Healthcare providers, such as hospitals and clinics, who use glucose monitors for patient care.
Potential partners in the wearable device and medical device industries.
Future customers for other diagnostic applications of Bio-RFID technology.

Proprietary Bio-RFID technology protected by patents.
Potential first-mover advantage in the non-invasive glucose monitoring market.
Potential for network effects as more users adopt the Bio-RFID technology.
Expertise in spectroscopy and medical device development.

什么因素可能推动KNW股价上涨？

Upcoming: Clinical trial results for the Bio-RFID glucose monitor, demonstrating accuracy and reliability.
Upcoming: FDA clearance for the Bio-RFID glucose monitor, enabling commercialization in the United States.
Ongoing: Strategic partnerships with medical device manufacturers or healthcare providers to expand market reach.
Ongoing: Development of new diagnostic applications for Bio-RFID technology beyond glucose monitoring.

KNW的主要风险是什么？

Potential: Technological challenges in achieving accurate and reliable results with Bio-RFID technology.
Potential: Regulatory delays in obtaining FDA clearance for the glucose monitor.
Ongoing: Competition from established players in the glucose monitoring market with existing CGM systems.
Ongoing: Limited financial resources to fund research, development, and commercialization efforts.
Potential: Intellectual property risks related to Bio-RFID technology and potential infringement by competitors.

KNW的核心优势是什么？

Proprietary Bio-RFID technology.
Potential for non-invasive glucose monitoring.
Experienced leadership team.
Potential for diverse applications of Bio-RFID.

KNW的劣势是什么？

Limited financial resources.
Dependence on successful development and commercialization of glucose monitor.
Lack of established market presence.
Small number of employees.

KNW有哪些机遇？

Growing demand for non-invasive glucose monitoring.
Potential for partnerships with medical device manufacturers.
Expansion into new diagnostic applications.
Licensing of Bio-RFID technology.

KNW面临哪些威胁？

Competition from established players in the glucose monitoring market.
Regulatory hurdles and delays.
Technological challenges in achieving accurate and reliable results.
Potential for obsolescence of Bio-RFID technology.

KNW的竞争对手是谁？

Gevo, Inc. — Focuses on renewable fuels and chemicals, different market. — (GVP)
Inter Parfums, Inc. — Operates in the fragrance industry, unrelated to medical devices. — (IPM)
Minim, Inc. — Networking products, different technology focus. — (MINM)
Metabolon, Inc. — Metabolomics and biomarker discovery, overlapping technology but different application. — (MTBL)
NYSE — Stock exchange operator, not a direct competitor. — (MYSE)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Ronald P. Erickson
Headquarters: Seattle, US
Employees: 12
Founded: 2006

AI Insight

AI analysis pending for KNW

常见问题

What does Know Labs, Inc. do?

Know Labs, Inc. is a technology company focused on developing and commercializing its proprietary Bio-RFID technology. This technology uses spectroscopy to analyze molecular signatures and is initially being applied to create a non-invasive glucose monitor. The company aims to provide real-time blood glucose level information without the need for traditional finger pricking, offering a more convenient and less painful alternative for individuals with diabetes. Know Labs is working towards regulatory approvals and commercialization of its glucose monitoring product.

What do analysts say about KNW stock?

AI analysis is pending for Know Labs, Inc. (KNW). Without analyst ratings or price targets, valuation hinges on the successful development and commercialization of its Bio-RFID technology, particularly its non-invasive glucose monitor. Investors should carefully consider the technological risks, regulatory hurdles, and competitive landscape before investing. The company's future performance depends on its ability to achieve accurate and reliable results with its technology and secure partnerships to expand its market reach.

What are the main risks for KNW?

Know Labs, Inc. faces several key risks, including technological challenges in achieving accurate and reliable results with its Bio-RFID technology. Regulatory delays in obtaining FDA clearance for its glucose monitor could also significantly impact its timeline and financial performance. The company also faces intense competition from established players in the glucose monitoring market, such as Medtronic and Abbott. Furthermore, Know Labs has limited financial resources, which could hinder its research, development, and commercialization efforts.